This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Remimazolam for general anaesthesia – first line

< Back

Remimazolam for general anaesthesia – first line


Anaesthetics, Pain Relief and ITU

March 2020

Remimazolam is in clinical development as an anaesthetic for induction and maintenance of general anaesthesia in adults. General anaesthesia is a technique of administering anaesthetic drugs into a vein (intravenous) or breathing anaesthetic gases into the lungs to put the patient into a reversible state of unconsciousness so that the patient is unaware of surgery and do not move or feel pain while it’s carried out. This enables the physician to perform surgery which would be extremely painful if the patient was awake and able to feel. Some serious complications associated with general anaesthesia include anaphylaxis, waking up during operation and, rarely death.

Remimazolam is an intravenous anaesthetic which is similar to the commonly used sleep-inducing drug midazolam, but it incorporates properties to make the offset of sedation faster and more predictable. If licensed, remimazolam will offer an additional first-line intravenous general anaesthetic treatment for induction and maintenance of general anaesthesia in adults.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts